with a fluorescent cell linker, PKH26. Spheroids were formed in 96-well plates (4Â104 cells/well/100ml). Spheroids were assembled into 3D shape by a robotic bio-fabrication system according to the pre-designed 3D data. The fabricated structures were perfusion cultured for 7 days to promote self-organization of the cells. Autologous 3D-printed AdMSCs structures were implanted around the cryo-injured urethra, immediately after injury, created by spraying liquid nitrogen for 20s. Sham operations were performed. Two weeks after implantation, the urethras were harvested for analyses.
INTRODUCTION AND OBJECTIVES: Recurrent urethral strictures can be managed endoscopically, but success rates approach 0% after 3 or more procedures. Scar modulation has the potential to be a therapeutic target for these patients. Amniofix (MiMedex, Marietta, GA) is a dehydrated human amnion/chorion membrane (dHACM) allograft designed to reduce scar tissue formation and promote healing, with a robust supportive literature in other body systems. We report the first clinical experience of adjuvant injectable dHACM placed at the time of urethrotomy in a population with otherwise high expected failure rates with urethrotomy alone.
METHODS: Between July 2016 and December 2016, a select group of patients with urethral stricture underwent urethrotomy and injection of dHACM into the incised scar tissue. Baseline demographics were collected. Patients were followed postoperative by symptoms, uroflowmetry (UF) and post-void residual (PVR) at least every 4 months. Successful treatment consisted of lack of additional procedures or self-catheterization for the treated stricture.
RESULTS: Twelve patients with median age 73 years were treated. Seven patients (58%) had prior pelvic radiation, and five patients (42%) had prior urethroplasty. The mean number of endoscopic procedures prior to injection was 2.5 (range 0-7). Successful treatment for the individual stricture was seen in 8 patients (67%) over the observation period. However, 2 of these patients developed other strictures requiring surgical intervention, one at the fossa navicularis and one in the prostatic urethra. There were no adverse effects noted from treatment. Median followup was 299 days .
CONCLUSIONS: Despite a heavily pretreated patient population including prior endoscopic treatments, radiation and/or urethroplasty, strictures treated with urethrotomy and adjuvant dHACM injection had a higher rate of success than expected with urethrotomy alone.
Source of Funding: Injectable dHACM was provided by the manufacturer, MiMedex.
PD33-06 EFFECTS OF CONTROLLED OXYGEN RELEASE FROM HOLLOW MICROPARTICLES FOR PROLONGED STEM CELL SURVIVAL AND IMPROVED ERECTILE FUNCTION
Yong Hyun Park*, Ae Ryang Jung, Ka Eun Kim, Mee Young Kim, Hyong Woo Moon, Kyu Won Lee, Ji Youl Lee, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: Postprostatectomy erectile dysfunction (ED) is the major problem for patients with prostate cancer. Recently, tissue-engineering approach has been attempted for postprostatectomy ED, but survival of stem cells until the ingrowth of blood vessels is one of the most important challenges in tissue engineering. In this study, we introduced perfluorooctane emulsion-loaded hollow microparticles (PFO-HP, Figure) for controlled oxygen delivery to facilitate a sustained and localized application into the cavernous nerve.
METHODS: We prepared the PFO-HP (oxygen supply) and PBSloaded HP (PBS-HP, non-supply of oxygen), and compared in vitro proliferation and differentiation of human adipose-derived stem cell (hADSCs) on the PFO-HP and PBS-HP in hypoxic condition. We also investigated the efficacy of hADSCs on the PFO-HP or PBS-HP on the cavernous nerve in a rat model of bilateral cavernous nerve crush injury (BCNI). Four weeks after surgery, erectile function was assessed by detecting the intracavernous pressure (ICP)/mean arterial pressure (MAP) level.
RESULTS: In hypoxic condition, the number of hADSCs on the PFO-HP increased for 5 days and then it gradually decreased. However, the initial cell number on the PFO-HP remained constant for up to 10 days, while the number of cells on the PBS-HP was rapidly decreased over time. After neuronal differentiation for 14 days, b-tubulin-III expression was significantly different between hADSCs on the PFO-HP and PBS-HP. In animal experiments, the ICP/MAP ratios in the PBS-HP and PFO-HP groups were significantly increased compared to those in the BCNI group. The ICP/MAP ratios between the PFO-HP and PBS-HP groups were not significantly different at 1 week after surgery, however, the ICP/MAP ratios in the PFO-HP group was significantly higher compared to those in the PBS-HP group at 2 and 4 weeks after surgery. PFO-HP group showed significantly increased smooth muscle/collagen ratio, nNOS content, phospho-eNOS protein expression, and cGMP level, compared with the BCNI and PBS-HP groups.
CONCLUSIONS: hADSCs on the PFO-HP can improve erectile function in a rat model of BCNI, in terms of controlled oxygen release from the PFO-HP for a sufficient time period, and prolonged stem cell survival until the ingrowth of new blood vessels.
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